Staar Results 2024 Comparison. Net sales up 19% for fourth quarter and 13% for fiscal 20231 icl sales up 22% for fourth quarter and 18% for fiscal 2023 provides fiscal 2024 sales outlook. The sales increase in the first quarter was driven by icl sales growth of $6.5 million, up 9%, and unit growth.
Staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo. Net sales up 19% for fourth quarter and 13% for fiscal 20231 icl sales up 22% for fourth quarter and 18% for fiscal 2023 provides fiscal 2024 sales outlook.
The Company Expects To Report Complete First Quarter Financial Results And Discuss Its Fiscal 2024 Outlook During Its Quarterly Earnings Call On Or About May 8, 2024.
Earnings per share (eps) also surpassed analyst estimates by 31%.
Staar Will Host A Conference Call And Webcast On Tuesday, May 7 At 4:15 P.m.
Staa), a leading developer, manufacturer and marketer of the evo family of implantable collamer® lenses (evo.
On Average During The Next 3 Years,.
Images References :
First Quarter 2024 Financial Results.
Net sales were $77.4 million for the first quarter of 2024, up 5% compared to $73.5 million reported in the prior year quarter.
Staa), A Leading Developer, Manufacturer And Marketer Of The Evo Family Of Implantable Collamer® Lenses (Evo.
Staar is the state’s testing program and is based on state curriculum standards in core subjects including rla, mathematics, science, and social studies.
Net Sales Were $77.4 Million For The First Quarter Of 2024, Up 5% Compared To $73.5 Million Reported In The Prior Year Quarter.